With ongoing clinical trials and preclinical studies supporting the efficacy of both EZH2 inhibitors and combination therapies, the landscape of treatment for CNS tumors is poised for transformative change, offering new hope for patients facing these challenging cancers. This evidence concerns the gene EZH2 and central nervous system neoplasm.